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Arylimidamides (AIAs) represent a new class of molecules that exhibit potent antileishmanial activity (50%
inhibitory concentration [IC50], <1 M) against both Leishmania donovani axenic amastigotes and intracel-
lular Leishmania, the causative agent for human visceral leishmaniasis (VL). A systematic lead discovery
program was employed to characterize in vitro and in vivo antileishmanial activities, pharmacokinetics,
mutagenicities, and toxicities of two novel AIAs, DB745 and DB766. They were exceptionally active (IC50 < 0.12
M) against intracellular L. donovani, Leishmania amazonensis, and Leishmania major and did not exhibit
mutagenicity in an Ames screen. DB745 and DB766, given orally, produced a dose-dependent inhibition of liver
parasitemia in two efficacy models, L. donovani-infected mice and hamsters. Most notably, DB766 (100 mg/kg
of body weight/day for 5 days) reduced liver parasitemia in mice and hamsters by 71% and 89%, respectively.
Marked reduction of parasitemia in the spleen (79%) and bone marrow (92%) of hamsters was also observed.
Furthermore, these compounds distributed to target tissues (liver and spleen) and had a moderate oral
bioavailability (up to 25%), a large volume of distribution, and an elimination half-life ranging from 1 to 2 days
in mice. In a repeat-dose toxicity study of mice, there was no indication of liver or kidney toxicity for DB766
from serum chemistries, although mild hepatic cell eosinophilia, hypertrophy, and fatty changes were noted.
These results demonstrated that arylimidamides are a promising class of molecules that possess good antil-
eishmanial activity and desirable pharmacokinetics and should be considered for further preclinical develop-
ment as an oral treatment for VL.
Leishmaniasis, a neglected tropical disease, is caused by
parasitic protozoa of the genus Leishmania, including 20 spe-
cies that are pathogenic for humans (21). Clinical manifesta-
tions of leishmaniasis mainly consist of cutaneous, mucocuta-
neous, visceral, and post-kala-azar dermal leishmaniasis, with
symptoms ranging from skin and mucosal ulceration to sys-
temic infection that is fatal if left untreated (6). An estimated
12 million people are currently infected with Leishmania, and
up to 350 million people in 88 countries are at risk of infection
(35). Approximately 2 million new cases of leishmaniasis are
believed to occur annually, with 1.5 million for cutaneous leish-
maniasis and 0.5 million for visceral leishmaniasis (VL). In
macrophages, Leishmania amastigotes adapt to thrive in an
acidic subcellular compartment, the parasitophorous vacuole
(PV; pH 5) (2), where they maintain a neutral intracellular
pH within the parasite by an energy-dependent process (9).
Multiple layers of membrane barriers (i.e., host macrophage
plasma membrane, phagolysosomal membrane, and Leishma-
nia amastigote plasma membrane) presumably present a for-
midable challenge for chemotherapeutic agents to target
Leishmania parasites in mammalian hosts.
Current chemotherapies for leishmaniasis have many limi-
tations, including resistance, cost, parenteral administration,
long treatment regimens, gastrointestinal intolerance, nephro-
toxicity, and/or teratogenicity (10, 18, 29, 30, 36). Since effec-
tive vaccines do not exist, there is an urgent need to develop
new chemotherapeutic candidates with improved pharmacoki-
netic and toxicologic properties for the treatment of leishman-
iasis.
In our efforts to identify promising antiprotozoal agents
from a library of aromatic diamidines and their analogues,
we have identified a new class of molecules, arylimidamides
(AIAs; previously referred to as “reversed” amidines [26, 27]),
that exhibited submicromolar 50% inhibitory concentrations
(IC50s) in the axenic Leishmania donovani amastigote assay
and the L. donovani-infected macrophage assay (26) and nano-
molar IC50s in Leishmania promastigote assays (22, 23). In
addition, AIAs demonstrated submicromolar IC50s against
Trypanosoma cruzi parasites (19, 24, 26), the causative agent
for the devastating Chagas’ disease (or human American
trypanosomiasis, also a neglected tropical disease). Here, we
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describe a systematic lead discovery program for AIAs to char-
acterize in vitro and in vivo antileishmanial activity, metabolism
and pharmacokinetics, mutagenicity, and toxicity. The objec-
tive of this program was to provide the scientific foundation for
future development of AIAs against leishmaniasis by deter-
mining the efficacies, pharmacokinetics, and toxicities of two
promising members (Fig. 1) of this class.
MATERIALS AND METHODS
Chemicals. DB745 {2,5-bis[2-ethoxy-4-(2-pyridylimino)aminophenyl]furan}
and DB766 {2,5-bis[2-(2-propoxy)-4-(2-pyridylimino)aminophenyl]furan} were
prepared according to a general, three-step route previously used to prepare
other 2,5-diarylfuran AIA compounds (27). Chemical data for DB745, DB766,
and synthetic intermediates are given in the supplemental material. Sodium
stibogluconate was from IP Albert David Ltd., Kolkata, India. All other chem-
icals were purchased from Fisher Scientific (Pittsburgh, PA) or Sigma-Aldrich
(St. Louis, MO), if not indicated otherwise.
In vitro susceptibility assays. The activities of DB745, DB766, and control
compounds against L. donovani axenic amastigotes and intracellular Leishmania
amazonensis or Leishmania major -lactamase-transfected parasites were deter-
mined as described previously (8). The activity of test compounds against intra-
cellular L. donovani LV82 was assessed microscopically as follows. Peritoneal
macrophages obtained from CD-1 mice were added to Lab-Tek chamber slides
(Nunc) at a density of 5  104 cells/well in a volume of 100 l in a macrophage
medium (RPMI 1640 with Glutamax [Gibco] and 10% heat-inactivated fetal
bovine serum [FBS], 50 units/ml penicillin, 50 g/ml streptomycin [pH 7.4]) and
were allowed to adhere overnight. Host cells were then infected overnight with
L. donovani LV82 stationary-phase promastigotes at a parasite/macrophage ratio
of 5:1 at 37°C in a 5% CO2 atmosphere. The following day, the used medium was
replaced with fresh medium containing either test compound or vehicle. After
incubation at 37°C for 72 h, slides were washed once with phosphate-buffered
saline, fixed with methanol, and stained with Giemsa (977 l distilled water, 23
l Giemsa diluent [3.1 mM dibasic potassium phosphate, 8.3 mM monobasic
sodium phosphate], 50 l Giemsa stain) for 25 min. The percentage of infected
macrophages in each chamber was determined microscopically at 1,000 mag-
nification. IC50s were determined by nonlinear regression analysis (four-param-
eter logistic curve) using SigmaPlot software. Compound activities against intra-
cellular L. donovani clinical isolates AG83-S, MC4-R, and MC8-R were
determined as described previously (11, 12). The toxicity of test compounds to
mouse peritoneal macrophages was measured as follows. Starch-elicited macro-
phages were obtained from CD-1 mice by peritoneal lavage and were seeded in
96-well microtiter plates in RPMI 1640 with 10% FBS, 50 units/ml penicillin and
50 g/ml streptomycin at a density of 1  106 cells/ml in 100 l. The plate was
incubated at 37°C under a 5% CO2 atmosphere. After 24 h, the medium was
replaced with 100 l fresh medium containing serial drug dilutions, and the plate
was incubated for another 72 h. CellTiter reagent (20 l; Promega, Madison, WI)
was then added to each well, and incubation was continued for an additional 2 to
4 h. The plates were read at 490 nm on a SpectraMax Plus 384 spectrophotom-
eter (Molecular Devices, Sunnyvale, CA), and IC50s were determined using the
four-parameter dose response equation described previously (8).
Antileishmanial efficacy against L. donovani in mice. Efficacy in the murine
model of VL was measured as previously described (8), except that all com-
pounds were dissolved in water prior to administration by the intraperitoneal
(i.p.) or oral (p.o.) route.
Antileishmanial efficacy against L. donovani in hamsters. An 11-day proce-
dure for screening compounds against VL in golden hamsters was adapted from
the 8-day method reported by Stauber et al. (25). L. donovani (WR378) meta-
cyclic promastigotes were obtained from cultured stationary-phase promasti-
gotes harvested from liver homogenates of infected hamsters as previously de-
scribed by Melby et al. (15). Five- to 6-week-old male Syrian hamsters
(Mesocricetus auratus) were obtained from Harlan (Indianapolis, IN), and each
hamster was infected intracardially (i.c.) with 2  108 metacyclic promastigotes
suspended in 200 l of Schneider’s insect medium. Compounds were adminis-
tered p.o. to L. donovani-infected hamsters, using a rubber gavage tube from day
4 postinfection (p.i.) to day 8 p.i., once daily. Controls consisted of two groups of
infected hamsters (n  4 per group). One group did not receive any treatment,
and the other group received p.o. miltefosine (30 mg/kg of body weight/day) that
served as the reference drug. Animals were euthanized on day 11 p.i. by CO2
asphyxiation. Liver, spleen, and femur were harvested in Schneider’s insect
medium supplemented with antibiotics.
Part of each liver and spleen tissue sample was used to prepare multiple touch
smears on glass slides. Caution was taken that the same lobe of the liver or the
same part of the spleen was used to prepare the smears from each tissue sample.
To harvest bone marrow from the femur, the femur was cleaned, trimming all fat
and muscles around the bone. A 3-ml syringe with 500 l of Schneider’s insect
medium was inserted into one end of the bone, and the marrow was flushed into
a microcentrifuge tube. The cells were centrifuged at 1,500 rpm for 2 min at
room temperature. Supernatant was removed, and the cell pellet was gently
broken and resuspended in the remaining medium. Smears were made on slides
by the use of 10 to 12 l of cell suspension. The smears were air dried, fixed in
methanol, and Giemsa (15%) stained. The parasite burden in the liver and
spleen of each animal was reported in Leishman-Donovan units (LDU), defined
as the organ mass (g) multiplied by the number of amastigotes per 1,000 mac-
rophage nuclei. The final numbers were converted to percentages of inhibition,
considering the numbers of vehicle-treated control tissue to be 100%.
pKa and logD7.4 determination and DNA melting temperature. The pKa and
logD7.4 values were measured by pION Inc. (Woburn, MA), using a spectropho-
tometric method, with methanol as a cosolvent (3). DNA melting studies (melt-
ing temperature [Tm]) were conducted with the reference model system,
poly(dA-dT), that has been extensively used with diamidines (13, 26, 27).
Metabolic stability, permeability, pharmacokinetics, and tissue distribution
studies. Metabolic stability of AIAs was evaluated using liver microsomes (Xeno-
Tech LLC, Lenexa, KS) derived from four relevant species, i.e., human, rat
(potential species for toxicity studies), mouse, and hamster, supplemented with
NADPH. Microsomal incubations were carried out according to a protocol
described previously (33) with modifications. Briefly, DB745 and DB766 were
dissolved in dimethyl sulfoxide and added to incubation buffer to achieve final
concentrations of 0.1 M, 1.0 M, and 10 M, containing 0.5% (vol/vol) organic
solvent. Reactions were allowed to proceed for up to 60 min at 37°C and were
stopped with 2 volumes of 7:1 methanol-water containing 0.1% trifluoroacetic
acid (vol/vol) and 30 nM internal standard. DB745 was used as internal standard
for DB766, and vice versa. After centrifugation (3,000  g), the supernatant
fractions were analyzed by high-performance liquid chromatography–tandem
mass spectrometry (HPLC-MS/MS; described below) to quantify the amount of
substrate remaining.
Permeability was measured using the Madin-Darby canine kidney (MDCK)
cell monolayer as previously described (31). Briefly, the compound (3 M for
DB766 or 25 M for furamidine) was added to the donor well (pH 7.4 in Hanks’
balanced salt solution supplemented with 25 mM D-glucose and 25 mM HEPES),
which was separated from the receiving well by the polarized MDCK cell mono-
layer grown on a polycarbonate membrane support. Transport (from apical to
basolateral) was carried out for 60 min at 37°C in an incubator. Compound
concentrations in donor and receiver wells were measured by HPLC-MS/MS to
calculate apparent permeability (Papp) (31).
Single-dose pharmacokinetics and tissue distribution of DB745 and DB766
were evaluated in mice. All animal experiments adhered to protocols approved
by the Institutional Animal Care and Use Committee at the University of North
Carolina at Chapel Hill. Male Swiss Webster mice (n  3 per time point) were
given DB745 or DB766 via p.o. gavage or tail vein bolus injection (intravenous
[i.v.]) as described previously (28) with modifications. Briefly, for i.v. adminis-
tration, DB745 or DB766 was initially dissolved in sterile water at 2 concen-
trations and then diluted 1:1 (vol/vol) with 2 sterile saline (1.8% [wt/vol]). This
dose solution was injected via a tail vein with administration over 10 to 20 s.
For p.o. administration, DB745 or DB766 was dissolved in sterile water to form
a clear solution at 5 mM or a gelatinous liquid at 20 mM and 40 mM. The dose
volume was 5 ml/kg for both i.v. and p.o. administration. Terminal blood and
tissue samples (liver, spleen, kidney, heart, and brain) were collected at selected
time points from 5 min up to 72 h postdose. Plasma was obtained by centrifu-
gation and processed for quantification of AIAs by HPLC-MS/MS (described
below).
Ames screening assay. The Ames screening assay was performed by SRI
International (Menlo Park, CA) as previously described (1, 17). DB745 and
FIG. 1. Chemical structures of two novel AIAs, DB745 and
DB766.
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DB766 were examined for their ability to induce genetic damage using the plate
incorporation method with Salmonella enterica serovar Typhimurium tester
strains TA98 and TA100, in the presence and absence of an Aroclor 1254-
induced rat liver S9 metabolic activation system (10% [vol/vol]). DB745 and
DB766 were dissolved in sterile water at 10 and 5 mg/ml, respectively, and then
serially diluted to achieve doses ranging from 1 to 1,000 g/plate (100 l) for
DB745 and 1 to 500 g/plate (100 l) for DB766. 2-Nitrofluorene and sodium
azide were used as positive controls when metabolic activation was absent.
2-Aminoanthracene was used as positive control when metabolic activation was
present. Sterile water and dimethyl sulfoxide (DMSO) were used as vehicle
controls. Test plates were compared with the control plates for their revertant
count and for the condition of the background bacterial lawn. A test compound
was considered a mutagen when the mean number of revertant colonies on the
test plates exceeded the mean solvent control counts by at least 2-fold.
Toxicity evaluation in female BALB/c mice. Single-dose escalation and 5-day
repeat-dose toxicity experiments were performed by SRI International. The
no-observable-adverse-effect levels (NOAELs) and maximum tolerated doses
(MTDs) were determined for DB745 and DB766 in female BALB/c mice fol-
lowing five daily p.o. or i.v. administrations. Dose formulations were prepared
fresh daily under yellow light by dissolving appropriate amounts of compound in
sterile water to achieve the target concentrations. Dosing volumes were 20 and
10 ml/kg for p.o. and i.v. administrations, respectively. For the single-dose esca-
lation experiment, mice (n  1 for each dose level per compound) were observed
for 2 days after dose administration, and the dose levels were 5, 10, and 30 mg/kg
i.v. and 25, 100, and 200 mg/kg p.o. for DB745 and 5, 20, and 50 mg/kg i.v. and
50 and 100 mg/kg p.o. for DB766. Doses larger than 100 mg/kg were not tested
for DB766 due to limited aqueous solubility. For the 5-day repeat-dose toxicity
experiment, mice (n  5 for each dose level per compound) were administered
a test compound once daily for five consecutive days and scheduled for necropsy
on day 6 (1 day after the last dose). Dose levels were selected based on results
from the single-dose escalation study described above and consisted of three
dose levels (low, mid, and high) for each compound per route of administration.
These dose levels were as follows: 5, 10, and 20 mg/kg/day i.v. and 25, 50, and 150
mg/kg/day p.o. for DB745; 5, 20, and 30 mg/kg/day i.v. and 25, 50, and 100
mg/kg/day p.o. for DB766. Control mice (n  5 for each route of administration)
were administered vehicle (sterile water) only. Body weights were recorded prior
to day 1 and prior to each necropsy. Clinical hematology and serum chemistry
were measured for blood samples collected 1 day after each last dose on day 6
prior to necropsy. Histopathologic examination of tissues retained in 10% neu-
tral buffered formalin was performed by a board-certified veterinary pathologist.
Sample preparation for analytical assays. A portion of the liver, one kidney,
and the whole spleen, heart, and brain were weighed and diluted with 2 volumes
of water (assuming 1 g of wet tissue is equal to 1 ml in volume), followed by
homogenization using a sonic dismembrator (model 100; Fisher Scientific, Wal-
tham, MA). Tissue homogenates or plasma samples (25 l) were mixed with 200
l of 7:1 (vol/vol) methanol-water containing 0.1% trifluoroacetic acid and in-
ternal standard (1 M for tissue homogenates or 30 nM for plasma samples),
followed by centrifugation (3,000  g) to pellet proteins. The supernatants were
dried using a 96-well microplate evaporator (model EVX-96; Apricot Designs
Inc., Covina, CA) under N2 at 50°C and reconstituted with 100 l 15% methanol
containing 0.1% trifluoroacetic acid before HPLC/UV analysis for tissue homog-
enates or HPLC-MS/MS analysis for plasma samples (described below).
HPLC/UV analyses of DB745 and DB766 were performed using a previously
described method (33) with modifications. All samples were monitored at 368
nm for the purpose of quantification with a flow rate of 0.5 ml/min. HPLC mobile
phases consisted of 35 mM formic acid and 15 mM ammonium formate in
HPLC-grade water (A) and 35 mM formic acid and 15 ammonium formate in
80:20 (vol/vol) acetonitrile-water (B). Mobile-phase composition began with 15%
B and was increased to 35% B over 0.5 min and further increased to 55% B over
the next 4.5 min. The mobile phase was then maintained at 95% B for 1 min to
wash the column, followed by reequilibrating with 15% B for 4 min before
injection of the next sample. Separation was carried out at 25°C. Typically, 20 l
of sample was injected. DB745 and DB766 eluted at 3.1 min and 3.5 min,
respectively, with baseline separation. The calibration curve for DB766 neat
standards ranged from 0.1 to 100 M with a detection limit of 0.05 M.
HPLC-MS/MS quantification of DB745 and DB766 was performed on an
Applied Biosystems (Foster City, CA) API 3000 or 4000 triple quadrupole mass
spectrometer equipped with a Turbo IonSpray interface (for electrospray ion-
ization) (MDS Sciex, San Francisco, CA). Typically, 4 to 5 l of sample was
injected. DB745 and DB766 were eluted from an Aquasil C18 analytical column
(2.1 by 50 mm, 5 m; Thermo Electron, Waltham, MA) and analyzed in positive
ion mode. HPLC mobile phases consisted of HPLC-grade water containing 0.3%
formic acid (C) and methanol containing 0.3% formic acid (D). After a 0.4-min
initial hold at 15% D, mobile-phase composition began with 15% D and was
increased to 80% D over 1.6 min, followed by a 1.0-min hold, at a flow rate of
0.35 ml/min. The column was then washed with 95% D for 1.3 min at a flow rate
of 0.5 ml/min and was reequilibrated with 15% D at a flow rate of 0.35 ml/min
for 0.5 min before injection of the next sample. The characteristic selected
reaction monitoring (SRM) transitions for DB745 and DB766 were m/z 547.43
426.1 and 575.3 3 454.1, respectively. The calibration curve for DB745 and
DB766 ranged from 2.5 to 10,000 nM, using a quadratic equation with 1/x
weighting.
Data analysis. Statistical analysis of in vivo antileishmanial activity was per-
formed by comparing the average liver parasitemia of treatment groups with that
of the untreated control group using Student’s unpaired t test (SigmaPlot 10.0);
a P value of 0.05 was considered significant. Statistical analysis of serum clinical
chemistry values was performed by the one-way analysis of variance (ANOVA),
followed by the Dunnett’s posttest if the ANOVA analysis was significant; a P
value of 0.05 was considered significant. Microsomal half-life (t1/2) values were
obtained by fitting the percentage of substrate remaining versus time curves to
the 1-phase exponential decay equation (C  C0  ekt; t1/2  0.693/k). Non-
compartmental pharmacokinetic analysis of plasma concentration versus time
curves was performed to obtain the area under the concentration-time curve
from 0 h to infinity (AUC0–), percentage of AUC that was extrapolated
(AUC_%Extrap), maximum plasma concentration (Cmax), time to reach Cmax
(Tmax), terminal elimination half-life (t1/2), clearance (CL), and steady-state




AUC(i.v.)  Dose(p.o.)  100%
RESULTS
In vitro antileishmanial activities. In vitro antileishmanial
activities of two novel AIAs, DB745 and DB766, were evalu-
ated using the axenic L. donovani amastigote assay and the
Leishmania-infected macrophage assays (Table 1). Both AIAs
exhibited submicromolar IC50s in all assays tested. Notably,
DB766 had IC50s less than 0.1 M in the intracellular Leish-
mania assays, substantially more potent than miltefosine,
paromomycin, and pentamidine and similar in potency to am-
photericin B. Both AIAs were selective against intracellular
Leishmania parasites compared to murine peritoneal macro-
phages, with selectivity indexes of 250 and 78 (based on the L.
donovani intracellular assay) for DB745 and DB766, respec-
tively.
Activity against antimony-resistant Leishmania isolates.
The potential of AIAs against drug-resistant Leishmania par-
asites was assessed using J774 macrophages infected with clin-
ical isolates of antimony-resistant L. donovani (Table 2).
DB745 and DB766 were active against these antimony-resis-
tant Leishmania parasites, with IC50s ranging from 0.064 to
0.16 M, similar to the IC50s against wild-type intracellular
Leishmania parasites shown in Table 1.
In vivo efficacy in the murine VL model. Prior to an in vivo
efficacy study, the acute overt toxicity of DB745 and DB766
was initially evaluated in uninfected female BALB/c mice via
repeat i.p. or p.o. administration (once daily for 5 days). When
DB766 was given p.o. at doses of 25 and 50 mg/kg/day for 5
days, mice showed no signs of any overt adverse effect. How-
ever, when given i.p. at a dose of 50 mg/kg/day, DB766 caused
some mild adverse effects (e.g., ruffled fur and hypoactivity),
although all mice survived the 5 days of treatment. In contrast,
when given i.p. at a dose of 50 mg/kg/day, DB745 caused
moderate adverse effects, with tremors, ruffled fur, and a ten-
dency to startle, but all mice survived the 5 days of treatment.
At a dose of 100 mg/kg/day i.p., DB745 was lethal to mice after
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two doses. These mice displayed severe hypoactivity, ataxia,
and tremors and had to be euthanized. Accordingly, appropri-
ate dose regimens (shown in Fig. 2) were selected for further
efficacy studies of mice. The highest DB766 (as a hydrochloride
salt) dose given was 100 mg/kg/day due to its limited aqueous
solubility.
The reductions in liver parasitemia of mice treated with
DB745 or DB766 compared to that of untreated controls are
shown in Fig. 2. When given i.p., both DB745 and DB766
showed dose-dependent inhibition of liver parasitemia. A max-
imum reduction of 63% was observed for each compound
administered at a dose of 30 mg/kg/day (DB766 was given for
5 days, but DB745 could be given for only 4 days due to adverse
events in the mice). Furthermore, DB766 exhibited a promis-
ing dose-dependent p.o. activity in this murine VL model, with
71% inhibition of liver parasitemia at a dose of 100 mg/kg/day
for 5 days. No signs of overt toxicity were observed for any of
the mice treated with DB766.
In vivo efficacy in the hamster VL model. Since the hamster
VL model is considered to be clinicopathologically and immu-
nopathologically more similar to human VL than to the murine
model (14), DB766 was further evaluated in our 11-day ham-
ster VL efficacy model. DB745 was not evaluated in this model
primarily due to its toxicity being greater than that of DB766.
The reductions in the parasitemia of three key tissues (i.e.,
liver, spleen, and bone marrow) in hamsters treated with
DB766 are shown in Table 3. When given p.o. at a dose of 100
mg/kg/day for 5 days, DB766 reduced parasitemia (LDU) in
liver, spleen, and bone marrow by 89%, 79%, and 92%, re-
spectively. Moreover, DB766 inhibited the bone marrow par-
asitemia in a dose-dependent manner (24%, 70%, and 92%
inhibition in LDU at doses of 30, 50, and 100 mg/kg/day for 5
days, respectively). However, using the same dose regimen,
DB766 exhibited a relatively flat dose response in liver and
spleen, ranging from 75% to 89% and 67% to 79% inhibition,
respectively. Miltefosine, given p.o. at a dose of 30 mg/kg/day
for 5 days as a positive control, afforded 88%, 79%, and 91%
inhibition of parasitemia (LDU) in liver, spleen, and bone
marrow, respectively.
Physicochemical properties and permeability. The pKa and
log P values for DB745 and DB766 were experimentally de-
termined using a UV spectrophotometric method (Table 1).
Unlike typical dicationic diamidines (e.g., pentamidine and
furamidine), which often have pKa values above 10 (13, 20),
DB745 and DB766 had near neutral pKa values (7.12 and 7.36,
respectively). Furthermore, both AIAs were moderately lipo-
philic at physiologic pH with logD7.4 values of 3.63 and 4.12,
respectively. DB766 was 20-fold more permeable across the
MDCK cell monolayer than furamidine (65 versus 3.3 nm/s for
Papp). DB745 and DB766 gave relatively small increases (6 to
7°C) in the DNA melting temperature (Tm), compared to the
diamidines, furamidine (25°C) (26) and pentamidine (12.8°C)
(Table 1).
In vitro metabolism in liver microsomes. Metabolism of
DB745 and DB766 was initially evaluated using pooled liver
microsomes supplemented with NADPH, and microsomal t1/2
values were measured by monitoring substrate disappearance
over time at three substrate concentrations (Table 4). In pooled
mouse liver microsomes, DB745 and DB766 microsomal t1/2 val-
ues appeared to be concentration dependent (longer half-lives at
higher substrate concentrations), indicating a saturable metabo-
lism observed in the concentration range tested (0.1 to 10 M).
Similar results were observed for both compounds by using rat
and hamster liver microsomes. In contrast, marginal substrate
depletion was detected for DB745 and DB766 by using human
liver microsomes with t1/2 values greater than 120 min at all
concentrations tested.
Pharmacokinetics in mice. Single-dose i.v. and p.o. pharma-
cokinetics of DB745 and DB766 were evaluated in mice to
examine the potential of these compounds as p.o. active drug
TABLE 2. In vitro antileishmanial activities of AIAs against
intracellular L. donovani clinical isolates
Compoundb
IC50 (M)a vs L. donovani:
AG83-S MC4-R MC8-R
DB745 0.13 	 0.01 0.15 	 0.02 0.16 	 0.03
DB766 0.090 	 0.013 0.076 	 0.005 0.064 	 0.010
Sb(V) 9.0 	 0.5 44 	 3 40 	 5
Sb(III) 6.2 	 1.8 32 	 5 26 	 5
a Mean 	 standard deviation of at least three independent determinations.
b Sb(V), sodium stibogluconate; Sb(III), sodium antimony tartrate.
TABLE 1. In vitro antileishmanial activities of AIAs and their physicochemical properties
Compound
IC50 (M)a vs:















DB745 0.50 	 0.15 0.018 	 0.007 0.12 	 0.02 0.026 	 0.011 4.5 	 1.4 7.12 3.82 3.63 7.1
DB766 0.50 	 0.10 0.036 	 0.005 0.087 	 0.015 0.014 	 0.004 2.8 	 0.8 7.36 4.41 4.12 6.0
Amphotericin B 0.098 	 0.013 0.066 	 0.012 0.14 	 0.01 0.21 	 0.05 8.2 	 1.1 ND ND ND ND
Miltefosine 8.5 	 1.2 2.7 	 0.3 15 	 3 25 	 3 24 	 15b ND ND ND ND
Paromomycin 
50 
50 19 	 3 25 	 2 
100 ND ND ND ND
Pentamidine 1.8 	 0.4 
50d 0.83 	 0.17 NDc 14 	 5 11.6 1.7 2.0 12.8f
a Mean 	 standard error of at least three independent determinations unless noted otherwise.
b Mean 	 range of two independent determinations.
c ND, not determined.
d Pentamidine is known to reduce the number of parasites per macrophage in in vitro experiments but not the number of infected macrophages as assessed here.
e Increase in DNA thermal melting of poly(dA-dT).
f See work by Stephens et al. (27).
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candidates. After a single p.o. dose of 25, 100, and 200 mol/kg
in mice (or 16.5, 66, and 131 mg/kg), DB745 maximum plasma
concentrations were 0.02, 0.40, and 1.68 M, respectively, with
terminal elimination t1/2 values ranging from 24 to 32 h (Table
5). DB745 p.o. bioavailability was dose dependent, improving
from 3.3% to 25% as the dose increased from 25 to 200 mol/
kg. After a single p.o. dose of 100 mol/kg (or 70 mg/kg) in
mice, DB766 Cmax and AUC0- were 4.4- and 2.4-fold higher
than those of DB745, respectively (Table 6). Furthermore, the
p.o. bioavailability of DB766 remained approximately the same
as that of DB745 (10.4% versus 9.3%). In addition, a large
volume of distribution was observed for both compounds, in-
dicating extensive tissue binding.
Tissue distribution in mice. Tissue concentrations of DB766
after i.v. and p.o. administration in mice were determined
using tissue homogenates from liver, spleen, kidney, heart, and
brain (Fig. 3). After a single i.v. dose of 7.5 mol/kg (or 5
mg/kg), DB766 maximum tissue concentrations were 10.7, 7.8,
and 7.3 g/g (or 18.7, 13.5, and 12.7 M) in liver, spleen, and
kidney, respectively, observed between 5 min and 2 h post-
dose. DB766 brain concentrations were much lower than the
corresponding plasma concentrations, indicating limited brain
uptake. DB766 concentrations in the heart were higher than
the corresponding plasma concentrations, albeit to a much
lower extent compared to liver, spleen, and kidney. After a
single p.o. dose of 100 mol/kg (or 70 mg/kg), DB766 maxi-
mum tissue concentrations were 26.3, 24.8, and 17.4 g/g (or
45.8, 43.1, and 30.3 M) in liver, spleen, and kidney, respec-
tively, all observed at 2 h postdose. Similar to i.v. administra-
tion, DB766 brain concentrations were lower than or close to
the corresponding plasma concentrations, whereas DB766
heart concentrations were higher, albeit to a much lower extent
than were those of the liver, spleen, and kidney. Furthermore,
DB766 concentrations in tissues that had the highest levels of







Mean SD Mean SD Mean SD
DB766, p.o. 10 10 10 NDb ND ND ND
30 75 17 67 24 24 50
50 76 21 74 29 70 22
100 89 6 79 8 92 6
Miltefosine, p.o. 30 88 8 79 6 91 9
a All percent inhibition data are presented as the means and standard devia-
tions of four replicate determinations in LDU.
b ND, not determined.
FIG. 2. In vivo efficacy levels of DB745 and DB766 in the murine VL model. Compounds were given i.p. (A and C) or p.o. (B and D) once daily
for 5 days to mice infected with L. donovani promastigotes. Results are presented as the percentage of reduction in liver parasitemia (LDU) versus
untreated controls. Miltefosine given i.p. served as a positive control in all groups. Bars and error bars denote the means and standard deviations,
respectively, of experimental groups containing four animals. *, P  0.05, compared to untreated control; #, mice in this group received only four
doses due to toxicity.
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the compound (liver and spleen) paralleled plasma concentra-
tions, indicating tissue t1/2 values similar to those of plasma.
Mutagenicity evaluation using the Ames screen. Potential
mutagenicity of DB745 and DB766 was assessed in a single
experiment with two different Salmonella serovar Typhi-
murium tester strains (TA98 and TA100) with and without
metabolic activation by using induced rat liver S9. DB745 was
cytotoxic to TA98 at doses of 100 g/plate and to TA100 at
doses of 50 g/plate in the absence of metabolic activation
and to TA98 at doses of 500 g/plate and to TA100 at doses
of 100 g/plate in the presence of metabolic activation.
DB766 was cytotoxic only to TA100 at doses of 100 g/plate
in the absence of metabolic activation and at doses of 500
g/plate in the presence of metabolic activation. No significant
increase in revertant colonies was seen with or without meta-
bolic activation for either DB745 (data not shown) or DB766
(Table 7), suggesting that these AIAs are not mutagenic.
Repeat-dose toxicity study of mice. A single-dose escalation
experiment was initially performed using adult female BALB/c
mice to determine appropriate dose levels for the 5-day repeat-
dose toxicity study. During the escalation experiment, all ani-
mals in the i.v. and p.o. treatment groups survived to their
scheduled necropsy. The only test article-related clinical ob-
servation was tremors, which affected one animal in the 30
mg/kg DB745 i.v. group and one animal in the 50 mg/kg DB766
i.v. group. Accordingly, appropriate dose levels were chosen
for the 5-day repeat-dose toxicity study and summarized in
Materials and Methods.
Mortality/morbidity and clinical observations. In the 5-day
repeat-dose toxicity study, all mice in the i.v. groups and the
p.o. DB766 groups survived until their scheduled necropsy
(i.e., 1 day after each last dose). All mice in the p.o. DB766
groups (25, 50, and 100 mg/kg/day) appeared to be normal
without significant clinical observations. However, mice that
received a high p.o. dose of DB745 at 150 mg/kg/day either
died or were euthanized in moribund condition on day 5. The
most prominent adverse effect was tremors that occurred in all
animals in the mid and high (10 and 20 mg/kg/day, respec-
tively) i.v. dose DB745 groups and the high (30 mg/kg/day) i.v.
dose DB766 group. These tremors generally started on day 2 or
3 and continued through day 6. For the high-p.o.-dose DB745
group, all mice were observed to have mild to severe ruffled fur
and tremors on day 4, and two mice became hyperactive on day
5. These mice were either found dead (one animal) or eutha-
nized in moribund condition (four animals) on day 5. For
FIG. 3. DB766 tissue concentrations in mice after a single i.v. (A) or
p.o. (B) administration of DB766. Plasma concentrations were plotted for
the purpose of comparison. Tissue concentrations were calculated assum-
ing that 1 g of wet tissue equals 1 ml in volume. Symbols and error bars
denote the means and standard errors, respectively, of triplicate determi-
nations.
TABLE 5. Pharmacokinetic measurements of DB745 after single
i.v. or p.o. administration in mice
Parametera
Pharmacokinetic measurement of DB745 after

















AUC0– (h  M) 0.56 4.5 0.5 5.6 30.0
AUC_%Extrap
(%)
9 3 42 19 13
Cmax (M) 0.37 4.24 0.02 0.40 1.68
Tmax (h) 0.0833 0.0833 2 2 2
t1/2 (h) 17 18 24 30 32
CL (ml/min/kg)b 45 28 28 28 28
Vss (liter/kg)c 36 22 57 71 76
F (%)d 3.3 9.3 25
a Noncompartmental analysis by WinNonlin 5.0.1, 1/y weighting, linear up/log
down.
b Observed total body clearance; for p.o. administration, corrected with F.
c Predicted steady-state volume of distribution for i.v. administration; pre-
dicted volume of distribution based on terminal phase.
d Calculated based on the AUC at 7.5 mol/kg i.v.
TABLE 6. Pharmacokinetic measurements of DB766 after single
i.v. or p.o. administration in mice
Parametera
Pharmacokinetic measurement of DB766 after














Cmax (M) 1.09 10.41 1.76
Tmax (h) 0.0833 0.0833 1
t1/2 (h) 22 24 48
CL (ml/min/kg)b 9.9 13.1 13.2
Vss (liter/kg)
c 14 15 54
F (%)d 10.4
a Noncompartmental analysis by WinNonlin 5.0.1, 1/y weighting, linear up/log
down.
b Observed total body clearance; for p.o. administration, corrected with F.
c Predicted steady-state volume of distribution for i.v. administration; pre-
dicted volume of distribution based on terminal phase.
d Calculated based on the AUC at 7.5 mol/kg i.v.
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surviving animals, no changes in body weight or organ weight
could be attributed to the treatment with either DB745 or
DB766. For moribund animals (mice treated with the high p.o.
dose of DB745 at 150 mg/kg/day), body weights and liver
weights were decreased by 24% and 30%, respectively, com-
pared to the final body weights and liver weights of the control
animals treated with the vehicle.
Clinical pathology evaluations. Since DB766 appeared to
accumulate in the mouse liver and kidney (Fig. 3), special
attention was paid to clinical chemistries that could indicate
liver or kidney toxicity (Table 8). No treatment-related in-
crease in liver enzymes or blood urea nitrogen was detected in
any groups except the moribund animals in the high-p.o.-dose
DB745 group. For the p.o. treatment groups, statistically sig-
nificant and dose-related increases in phosphorus levels (up to
74% compared to the control animals) were observed and the
largest increase was associated with the moribund animals in
the high-p.o.-dose DB745 group, whereas slight increases in
phosphorus levels were noted in the i.v. treatment groups.
Other statistically significant changes in clinical chemistries of
surviving animals were noted, but are considered to be too
small to be toxicologically relevant. In addition, no treatment-
related changes in hematology were found in either the i.v. or
the p.o. treatment groups (data not shown).
Gross necropsy and histopathology. The only treatment-
related gross necropsy finding was discolored pale liver, which
was observed in moribund animals in the high-p.o.-dose
DB745 group. Other findings, including discolored or rough-
ened heart and mottled lung, were noted in most groups.
However, these findings are considered to be attributable to
spontaneous changes in BALB/c mice as indicated by mi-
croscopic examination of the heart tissue and results of
sodium pentobarbital euthanasia, respectively. No organ
weight changes could be attributed to treatment with either
DB745 or DB766, except for moribund animals in the high-
p.o.-dose DB745 group, where a reduction in liver weight
(30%) compared to that of the control group was present.
TABLE 7. DB766 mutagenicity evaluation using the Ames screen
Strain Compound Dose/plate(g)








TA98 DB766 1 43 	 4.2 38 	 2.1
5 48 	 0.0 29 	 0.0
10 38 	 9.2 29 	 2.8
50 39 	 7.1 28 	 8.5
100 38 	 0.0 34 	 6.4
500 47 	 1.4 28 	 8.5
Sterile water 30 	 4.2 36 	 2.1
DMSO 42 	 0.0 32 	 3.5
2-Aminoanthracene 2 2,744 	 120
2-Nitrofluorene 5 1,573 	 140
TA100 DB766 1 159 	 8 152 	 1
5 154 	 9 145 	 0
10 148 	 1 148 	 3
50 135 	 21 79 	 27
100 98 	 16 Toxic
500 Toxic Toxic
Sterile water 153 	 1 148 	 13
DMSO 171 	 18 130 	 13
2-Aminoanthracene 2 2,563 	 59
Sodium azide 5 1,882 	 110
a Mean 	 standard deviation of duplicate determinations. Toxic, test com-
pound is cytotoxic to the Salmonella test strain.
TABLE 8. Serum clinical chemistry evaluations for the 5-day repeat-dose toxicity study in mice
Compound Dose(mg/kg/day)
Mean (SD)a
AST (U/liter) ALT (U/liter) BUN (mg/dl) ALP (U/liter) PHO (mg/dl)
Vehicle (i.v.) 0 65 (14) 34 (10) 20 (2) 134 (10) 6.1 (1.2)
DB745 (i.v.) 5 80 (49) 43 (15) 18 (2) 113 (14) 7.1 (0.7)
10 80 (12) 40 (16) 24 (6) 118 (16) 8.1 (0.9)
20 89 (24) 57 (30) 27 (3) 107 (7) 7.3 (1.1)
DB766 (i.v.) 5 76 (30) 36 (9) 19 (1) 103 (12) 7 (1)
20 76 (18) 50 (23) 26 (3) 104 (26) 6.5 (0.4)
30 73 (27) 35 (8) 24 (4) 118 (7) 7.6 (0.6)
Vehicle (p.o.) 0 70 (16) 36 (8) 29 (5) 129 (23) 5.3 (0.3)
DB745 (p.o.) 25 67 (10) 31 (6) 29 (6) 136 (19) 6.9 (0.4)c
50 77 (14) 34 (8) 27 (4) 130 (25) 7.2 (0.8)d
150b 770 (370) 220 (100) 52 (13) 120 (7) 9.2 (1.8)
DB766 (p.o.) 25 75 (26) 44 (24) 27 (2) 126 (25) 7.0 (1.2)c
50 90 (16) 45 (19) 25 (4) 123 (11) 8.3 (1.0)d
100 68 (9) 34 (11) 29 (2) 142 (18) 7.5 (1.0)d
a Mean (standard deviation [SD]) of five animals. AST, aspartate aminotransferase; ALT, alanine aminotransferase; BUN, blood urea nitrogen; ALP, alkaline
phosphatase; PHO, phosphorus.
b One animal in this group died before scheduled necropsy, and the other four were in moribund condition on day 5. Values in this group represent means and SD
of four moribund animals and were not included in statistical significance analysis.
c P  0.05.
d P  0.01.
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The key histopathology findings are minimal to mild hepatic
cell eosinophilia, hypertrophy, and fatty changes that were
directly related to the high i.v. and high p.o. doses of DB745
and DB766. One moribund animal in the high-p.o.-dose
DB745 group showed a moderate fatty change in the liver.
In contrast, liver necrosis, gastric inflammation, edema, and
hemorrhage, as well as splenic lymphoid depletion were
found only in moribund animals from the high-p.o.-dose
DB745 group at 150 mg/kg/day and are considered to have
been secondary findings related to stress.
Taken together, based on the morbidity, clinical observa-
tions, clinical chemistry, and histopathology, the NOAELs and
MTDs for female BALB/c mice treated p.o. or i.v. once a day
for five consecutive days are summarized in Table 9.
DISCUSSION
In this work, we have evaluated two novel AIAs regarding
their in vitro and in vivo antileishmanial activity, physicochem-
ical and pharmacokinetic properties, mutagenicity, and toxic-
ity. Our data demonstrate that AIAs are promising preclinical
development candidates for the p.o. treatment of VL. First,
AIAs are potent leishmanicidals with submicromolar IC50s
against intracellular amastigotes. In particular, DB766 is
among the most potent, with an IC50 of 0.1 M (Table 1),
which is similar to that of amphotericin B and substantially
more active than miltefosine and paromomycin. Moreover,
AIAs are equally active against wild-type and antimony-resis-
tant Leishmania parasites, suggesting a potential role as a
rescue treatment for antimony treatment failures or as a part-
ner in combination therapy with currently used antileishmani-
als. Second, AIAs are active in both mouse and hamster VL
models, markedly reducing liver parasitemia in these systems.
In addition, DB766 caused a substantial decrease in spleen and
bone marrow parasitemia in the hamster VL model, which was
considered to be clinicopathologically and immunopathologi-
cally more similar to human VL than the murine model (14).
Third, AIAs have desirable physicochemical and pharmacoki-
netic properties, including moderate lipophilicity, p.o. bioavail-
ability, and metabolic stability, as well as preferred tissue dis-
tribution to target organs (liver and spleen). Considering that
species-dependent rates of metabolism were observed (Table
4), a slower metabolism in humans may benefit efficacy and
dosing frequency, although a potential increase in toxicity
needs to be considered for dose selection. Fourth, DB745 and
DB766 are not mutagenic in the Ames screening assay using
two Salmonella serovar Typhimurium tester strains (Table 7).
Finally, the 5-day repeat-dose toxicity study of mice showed
that DB766 was better tolerated than was DB745, as indicated
by the NOAELs and MTDs following i.v. administration (di-
rect comparison following p.o. administration was not possible
due to insufficient data). Furthermore, no treatment-related
changes in hematology, liver function tests, or kidney function
tests (Table 8) were found in DB766-treated mice. It should be
noted that higher doses of DB766 (i.e., 
100 mg/kg) were not
examined for efficacy or toxicity due to the limited aqueous
solubility of this hydrochloride salt. Studies are in progress
evaluating efficacy and toxicity of the mesylate salt of DB766,
as this mesylate salt afforded markedly improved aqueous sol-
ubility.
Although AIAs are structural analogues of cationic diami-
dines, e.g., pentamidine and furamidine, they differ signifi-
cantly in physicochemical properties and bioavailability. AIAs
are much more lipophilic than diamidines at neutral pHs based
on logD7.4 values (4.12 and 2.0 for DB766 and furamidine
[13], respectively). In contrast to the extremely low p.o. bio-
availability exhibited by cationic diamidines (e.g., 0.24% for
furamidine in mice) (our unpublished data), AIAs have mod-
erate p.o. bioavailability (up to 25% in mice). Furthermore,
AIAs are generally more active against intracellular parasites,
Leishmania and T. cruzi, and less active against Trypanosoma
brucei subsp. brucei than their diamidine counterparts (34).
This difference in the antiparasitic activity may indicate dis-
tinctions in mechanism of action and/or cellular uptake be-
tween AIAs and diamidines.
It is still unclear how AIAs exert their antileishmanial effect.
Recent studies demonstrated that AIAs caused profound ul-
trastructural alterations in the nuclei and mitochondria, as well
as in the microtubule organization of T. cruzi (24). Similarly,
pentamidine induced prominent mitochondrial distention and
disrupted the mitochondrial membrane potential in Leishma-
nia parasites (7, 32) and in rat liver mitochondria (16). Pent-
amidine was also shown to inhibit the plasma membrane Ca2-
ATPase of T. brucei (5). Studies into pentamidine resistance in
Leishmania mexicana also suggested a mitochondrial target in
the mode of action for cationic diamidines (4). Considering
that DB745 and DB766 bind to synthetic poly(dA-dT) DNA,
albeit with much weaker affinity than to pentamidine (Table 1),
the mitochondrion may still play a role in the mode of action
for AIAs in Leishmania parasites. However, recent studies with
new AIAs showed that these compounds retained submicro-
molar antileishmanial activity even when DNA binding is lack-
ing [Tm
(AT)  2°C, where Tm
(AT) is the increase in DNA
thermal melting of poly(dA-dT)] (our unpublished data).
Thus, processes that do not require DNA binding could also
play a role in parasite killing. Further study into potential
mechanisms of action of AIAs in Leishmania is in progress.
Compared to cationic diamidines, AIAs displayed apprecia-
bly higher p.o. bioavailability, exhibiting promising p.o. activity
in both mouse and hamster VL models. The enhanced p.o.
bioavailability of AIAs is likely due to a combination of an
improved gastrointestinal absorption as a result of increased
lipophilicity at physiologic pHs (Table 1) and potentially sat-
urated metabolism at higher doses (Table 4). The observed
saturable metabolism of DB745 in mouse liver microsomes
could partially contribute to its dose-dependent p.o. bioavail-
ability in mice (Table 5). In addition, increased lipophilicity
and near neutral pKa values provide a possible explanation for
TABLE 9. NOAELs and MTDs of AIAs in female BALB/c mice




p.o. i.v. p.o. i.v.
DB745 50 5 Between 50 and 150 10
DB766a 50 20 100 30
a Doses higher than 100 mg/kg/day were not tested due to limited aqueous
solubility.
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the potent activity of AIAs against intracellular Leishmania
parasites, because lipophilic AIAs should traverse the host
macrophage plasma membrane and phagolysosomal mem-
brane via passive diffusion at physiologic pHs before reaching
parasites. Once in the phagolysosomes or PV, where the pH
value is 5 (2), AIAs could form cations before being taken up
by the parasite via an unknown process in order to exert their
antileishmanial activities. It would be interesting to confirm the
above hypothesis and identify the uptake process, as it may
have implications in determining potential drug resistance.
AIAs accumulated in the mouse liver and spleen at the
highest concentrations among all tissues examined, a poten-
tially positive attribute because the liver and spleen are target
organs of chemotherapeutic agents for VL and Leishmania
parasites predominantly reside in these organs, in addition to
the bone marrow (6). Furthermore, appreciable concentrations
of AIAs were detected in the kidney and heart (concentrations
in the bone marrow were not determined in this study),
whereas markedly lower concentrations were detected in the
brain, suggesting limited central nervous system (CNS) pene-
tration by AIAs. The extensive tissue distribution and accumu-
lation described above are consistent with the large volume of
distribution obtained from the pharmacokinetic analysis of the
plasma concentration-time profiles (Tables 5 and 6) and have
raised toxicity concerns, particularly for the spleen, liver, and
kidney. Accordingly, biomarkers for liver or kidney toxicity and
histopathology on spleen, liver, and kidney were specifically
included in the 5-day repeat-dose toxicity study of mice. Re-
sults showed that DB766 did not cause significant increase in
liver enzymes or blood urea nitrogen (Table 8), despite rela-
tively high liver and kidney concentrations even after a single
dose (Fig. 3). DB745 and DB766 caused minimal to mild
hepatic cell eosinophilia, hypertrophy, and fatty changes at the
high i.v. and p.o. doses tested, which were the primary deter-
minants for their NOAEL and MTD levels (Table 9). More-
over, increases in phosphorus levels following i.v. and p.o.
treatment with DB745 and DB766 are not likely due to kidney
or bone marrow damage because microscopic examination of
these two tissues did not reveal any treatment-related dam-
ages. Another possible cause of increased phosphorus levels is
calcium deposition (mineralization) in tissues. Since cardiac
mineralization is a commonly reported spontaneous change in
BALB/c mice and was also present in this study of both i.v. and
p.o. treatment groups, the changes in phosphorus levels may,
in part, have been secondary to the process of cardiac miner-
alization in these mice.
The high tissue concentrations (relative to in vitro IC50s) of
AIAs may explain the observed promising efficacy in mice (Fig.
3). However, it was anticipated that the levels of compound in
the liver and spleen should have resulted in near complete
reduction of parasitemia. Studies are in progress to understand
how AIAs are distributed within the target organs (liver,
spleen, and bone marrow) and subcellularly, as it may provide
an explanation for the above-described disconnect between
tissue concentrations and efficacy. Moreover, additional phar-
macokinetic and efficacy studies are ongoing in the hamster VL
model to investigate pharmacokinetic-pharmacodynamic rela-
tionships and the potential impact of Leishmania infection on
pharmacokinetics.
In conclusion, studies presented here confirmed that AIAs
possess potent antileishmanial activities in vitro and good ac-
tivities in animal models of VL. Our data demonstrate that
DB766 is a promising preclinical development candidate for
the p.o. treatment of VL, and other AIA analogues should be
further explored to obtain improved efficacy and safety pro-
files.
ACKNOWLEDGMENTS
This study was supported by a grant from the Bill and Melinda Gates
Foundation and by contract N01-AI-60011 with SRI International
from the National Institute of Allergy and Infectious Diseases.
We are grateful to Stephen Wring (Scynexis Inc., NC) and Brian
Vesely (College of Public Health, University of South Florida, FL) for
providing help on the MDCK transport study and technical assistance,
respectively.
REFERENCES
1. Ames, B. N., J. McCann, and E. Yamasaki. 1975. Methods for detecting
carcinogens and mutagens with the Salmonella/mammalian-microsome mu-
tagenicity test. Mutat. Res. 31:347–364.
2. Antoine, J. C., E. Prina, C. Jouanne, and P. Bongrand. 1990. Parasitopho-
rous vacuoles of Leishmania amazonensis-infected macrophages maintain an
acidic pH. Infect. Immun. 58:779–787.
3. Avdeef, A. 2001. Physicochemical profiling (solubility, permeability and
charge state). Curr. Top. Med. Chem. 1:277–351.
4. Basselin, M., H. Denise, G. H. Coombs, and M. P. Barrett. 2002. Resistance
to pentamidine in Leishmania mexicana involves exclusion of the drug from
the mitochondrion. Antimicrob. Agents Chemother. 46:3731–3738.
5. Benaim, G., C. Lopez-Estrano, R. Docampo, and S. N. Moreno. 1993. A
calmodulin-stimulated Ca2 pump in plasma-membrane vesicles from
Trypanosoma brucei; selective inhibition by pentamidine. Biochem. J.
296(Pt. 3):759–763.
6. Chappuis, F., S. Sundar, A. Hailu, H. Ghalib, S. Rijal, R. W. Peeling, J.
Alvar, and M. Boelaert. 2007. Visceral leishmaniasis: what are the needs for
diagnosis, treatment and control? Nat. Rev. Microbiol. 5:873–882.
7. Croft, S. L., and R. P. Brazil. 1982. Effect of pentamidine isethionate on the
ultrastructure and morphology of Leishmania mexicana amazonensis in vitro.
Ann. Trop. Med. Parasitol. 76:37–43.
8. Delfin, D. A., R. E. Morgan, X. Zhu, and K. A. Werbovetz. 2009. Redox-
active dinitrodiphenylthioethers against Leishmania: synthesis, structure-ac-
tivity relationships and mechanism of action studies. Bioorg. Med. Chem.
17:820–829.
9. Glaser, T. A., J. E. Baatz, G. P. Kreishman, and A. J. Mukkada. 1988. pH
homeostasis in Leishmania donovani amastigotes and promastigotes. Proc.
Natl. Acad. Sci. U. S. A. 85:7602–7606.
10. Kumar, D., A. Kulshrestha, R. Singh, and P. Salotra. 2009. In vitro suscep-
tibility of field Isolates of Leishmania donovani to miltefosine and ampho-
tericin B: correlation with sodium antimony gluconate susceptibility and
implications for treatment in areas of endemicity. Antimicrob. Agents Che-
mother. 53:835–838.
11. Mandal, S., M. Maharjan, S. Ganguly, M. Chatterjee, S. Singh, F. Buckner,
and R. Madhubala. 2009. High-throughput screening of amastigotes of
Leishmania donovani clinical isolates against drugs using a colorimetric
-lactamase assay. Indian J. Exp. Biol. 47:475–479.
12. Mandal, S., M. Maharjan, S. Singh, M. Chatterjee, and R. Madhubala.
2010. Assessing aquaglyceroporin gene status and expression profile in an-
timony-susceptible and -resistant clinical isolates of Leishmania donovani
from India. J. Antimicrob. Chemother. 65:496–507.
13. Mathis, A. M., A. S. Bridges, M. A. Ismail, A. Kumar, I. Francesconi, M.
Anbazhagan, Q. Hu, F. A. Tanious, T. Wenzler, J. Saulter, W. D. Wilson, R.
Brun, D. W. Boykin, R. R. Tidwell, and J. E. Hall. 2007. Diphenyl furans and
aza analogs: effects of structural modification on in vitro activity, DNA
binding, and accumulation and distribution in trypanosomes. Antimicrob.
Agents Chemother. 51:2801–2810.
14. Melby, P. C., B. Chandrasekar, W. Zhao, and J. E. Coe. 2001. The hamster
as a model of human visceral leishmaniasis: progressive disease and impaired
generation of nitric oxide in the face of a prominent Th1-like cytokine
response. J. Immunol. 166:1912–1920.
15. Melby, P. C., Y. Z. Yang, J. Cheng, and W. Zhao. 1998. Regional differences
in the cellular immune response to experimental cutaneous or visceral in-
fection with Leishmania donovani. Infect. Immun. 66:18–27.
16. Moreno, S. N. 1996. Pentamidine is an uncoupler of oxidative phosphoryla-
tion in rat liver mitochondria. Arch. Biochem. Biophys. 326:15–20.
17. Mortelmans, K., and E. Zeiger. 2000. The Ames Salmonella/microsome
mutagenicity assay. Mutat. Res. 455:29–60.
18. Olliaro, P. L., P. J. Guerin, S. Gerstl, A. A. Haaskjold, J. A. Rottingen, and
S. Sundar. 2005. Treatment options for visceral leishmaniasis: a systematic
VOL. 54, 2010 AIAs AGAINST LEISHMANIASIS 2515
 on M









review of clinical studies done in India, 1980–2004. Lancet Infect. Dis.
5:763–774.
19. Pacheco, M. G., C. F. da Silva, E. M. de Souza, M. M. Batista, P. B. da Silva,
A. Kumar, C. E. Stephens, D. W. Boykin, and N. Soeiro Mde. 2009. Trypano-
soma cruzi: activity of heterocyclic cationic molecules in vitro. Exp. Parasitol.
123:73–80.
20. Paul, M., R. Durand, Y. Boulard, T. Fusai, C. Fernandez, D. Rivollet, M.
Deniau, and A. Astier. 1998. Physicochemical characteristics of pentamidine-
loaded polymethacrylate nanoparticles: implication in the intracellular drug
release in Leishmania major infected mice. J. Drug Target. 5:481–490.
21. Pearson, R. D., and A. Q. Sousa. 1996. Clinical spectrum of leishmaniasis.
Clin. Infect. Dis. 22:1–13.
22. Rosypal, A. C., J. E. Hall, S. Bakunova, D. A. Patrick, S. Bakunov, C. E.
Stephens, A. Kumar, D. W. Boykin, and R. R. Tidwell. 2007. In vitro activity
of dicationic compounds against a North American foxhound isolate of
Leishmania infantum. Vet. Parasitol. 145:207–216.
23. Rosypal, A. C., K. A. Werbovetz, M. Salem, C. E. Stephens, A. Kumar, D. W.
Boykin, J. E. Hall, and R. R. Tidwell. 2008. Inhibition by dications of in vitro
growth of Leishmania major and Leishmania tropica: causative agents of old
world cutaneous leishmaniasis. J. Parasitol. 94:743–749.
24. Silva, C. F., M. B. Meuser, E. M. De Souza, M. N. Meirelles, C. E. Stephens,
P. Som, D. W. Boykin, and M. N. Soeiro. 2007. Cellular effects of reversed
amidines on Trypanosoma cruzi. Antimicrob. Agents Chemother. 51:3803–
3809.
25. Stauber, L. A., E. M. Franchino, and J. Grun. 1958. An eight-day method for
screening compounds against Leishmania donovani in the golden hamster. J.
Eukaryot. Microbiol. 5:269–273.
26. Stephens, C. E., R. Brun, M. M. Salem, K. A. Werbovetz, F. Tanious, W. D.
Wilson, and D. W. Boykin. 2003. The activity of diguanidino and “reversed”
diamidino 2,5-diarylfurans versus Trypanosoma cruzi and Leishmania dono-
vani. Bioorg. Med. Chem. Lett. 13:2065–2069.
27. Stephens, C. E., F. Tanious, S. Kim, W. D. Wilson, W. A. Schell, J. R. Perfect,
S. G. Franzblau, and D. W. Boykin. 2001. Diguanidino and “reversed”
diamidino 2,5-diarylfurans as antimicrobial agents. J. Med. Chem. 44:1741–
1748.
28. Sturk, L. M., J. L. Brock, C. R. Bagnell, J. E. Hall, and R. R. Tidwell. 2004.
Distribution and quantitation of the anti-trypanosomal diamidine 2,5-bis(4-
amidinophenyl)furan (DB75) and its N-methoxy prodrug DB289 in murine
brain tissue. Acta Trop. 91:131–143.
29. Sundar, S., T. K. Jha, C. P. Thakur, J. Engel, H. Sindermann, C. Fischer, K.
Junge, A. Bryceson, and J. Berman. 2002. Oral miltefosine for Indian visceral
leishmaniasis. N. Engl. J. Med. 347:1739–1746.
30. Sundar, S., H. Mehta, A. V. Suresh, S. P. Singh, M. Rai, and H. W. Murray.
2004. Amphotericin B treatment for Indian visceral leishmaniasis: conven-
tional versus lipid formulations. Clin. Infect. Dis. 38:377–383.
31. Troutman, M. D., and D. R. Thakker. 2003. Novel experimental parameters
to quantify the modulation of absorptive and secretory transport of com-
pounds by P-glycoprotein in cell culture models of intestinal epithelium.
Pharm. Res. 20:1210–1224.
32. Vercesi, A. E., and R. Docampo. 1992. Ca2 transport by digitonin-perme-
abilized Leishmania donovani. Effects of Ca2, pentamidine and WR-6026
on mitochondrial membrane potential in situ. Biochem. J. 284(Pt. 2):463–
467.
33. Wang, M. Z., J. Y. Saulter, E. Usuki, Y. L. Cheung, M. Hall, A. S. Bridges,
G. Loewen, O. T. Parkinson, C. E. Stephens, J. L. Allen, D. C. Zeldin,
D. W. Boykin, R. R. Tidwell, A. Parkinson, M. F. Paine, and J. E. Hall.
2006. CYP4F enzymes are the major enzymes in human liver microsomes
that catalyze the O-demethylation of the antiparasitic prodrug DB289
[2,5-bis(4-amidinophenyl)furan-bis-O-methylamidoxime]. Drug Metab.
Dispos. 34:1985–1994.
34. Werbovetz, K. 2006. Diamidines as antitrypanosomal, antileishmanial and
antimalarial agents. Curr. Opin. Invest. Drugs 7:147–157.
35. WHO. Leishmaniasis: the global trend. WHO, Geneva, Switzerland. http:
//www.who.int/neglected_diseases/integrated_media_leishmaniasis/en/index
.html.
36. Yeates, C. 2002. Sitamaquine (GlaxoSmithKline/Walter Reed Army Insti-
tute). Curr. Opin. Invest. Drugs 3:1446–1452.
2516 WANG ET AL. ANTIMICROB. AGENTS CHEMOTHER.
 on M
ay 13, 2015 by U
niversity of K
ansas
http://aac.asm
.org/
D
ow
nloaded from
 
